Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy-Reference-Cited by-同舟云学术

Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy

Published:2016-05-31 Issue:6 Volume:7 Page:915-918
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Okamoto Masahide¹,Okamoto Mitsuhiro¹,Gotoh Koro¹,Masaki Takayuki¹,Ozeki Yoshinori¹,Ando Hisae¹,Anai Manabu¹,Sato Asami¹,Yoshida Yuichi¹,Ueda So¹,Kakuma Tetsuya¹,Shibata Hirotaka¹

Affiliation:

1. Department of Endocrinology, Metabolism, Rheumatology and Nephrology Faculty of Medicine Oita University Oita Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.12531

Reference10 articles.

1. Nivolumab: A Review of Its Use in Patients with Malignant Melanoma

2. Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

3. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

4. Precipitation of autoimmune diabetes with anti‐PD‐1 immunotherapy;Hughes J;Diabetes Care,2015

5. Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine toxicity of cancer immunotherapy;International Journal of Molecular and Immuno Oncology;2024-08-31

2. Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria;Diseases;2024-02-14

3. Clinically Approved Monoclonal Antibodies–based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care;Clinical Therapeutics;2024-01

4. Cancer as a global health crisis with deep evolutionary roots;Global Transitions;2024

5. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review;Frontiers in Public Health;2023-12-01